<DOC>
	<DOCNO>NCT00495872</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose valproic acid combination either dasatinib , erlotinib hydrochloride , lapatinib , lenalidomide , sorafenib , SU011248 ( sunitinib malate ) give patient advanced cancer . The safety combination study drug study well .</brief_summary>
	<brief_title>Valproic Acid-Based 2-Agent Oral Regimens Patients With Advanced Solid Tumor</brief_title>
	<detailed_description>The Study Drugs : Valproic acid design use anti-seizure medication . It think also anticancer activity activating ( `` turn '' ) tumor-fighting gene , may cause cancer cell death . Dasatinib design change function gene . By change function gene , may prevent cancer grow spread . Erlotinib hydrochloride design block activity protein find surface many tumor cell may control tumor growth survival . This may stop tumor grow . Lapatinib design block activity certain molecule . These molecule play part growth cancer cell particularly important growth inflammatory breast cancer tumor . Lenalidomide design change body 's immune system . It may also interfere development tiny blood vessel help support tumor growth . Therefore , theory , may decrease prevent growth cancer cell . Sorafenib design block function cancer protein well tumor blood-vessel forming protein . Sunitinib malate design block pathway control important event growth blood vessel essential growth cancer . Study Administration : If find eligible take part study , study doctor decide drug receive valproic acid , base upon particular disease . You begin take valproic acid plus either dasatinib , erlotinib hydrochloride , lapatinib , lenalidomide , sorafenib , sunitinib malate . One ( 1 ) cycle either 21 28 day long , depend study drug combination receive . You take valproic acid mouth twice day 7 day row . You 7-day `` rest '' period take drug . You also take either sorafenib sunitinib malate mouth twice day continuously 21 day , dasatinib , erlotinib hydrochloride , lapatinib , lenalidomide mouth twice day continuously 28 day . Depending stage study , take study drug either twice day . Study Visits : You tests/procedures designate study visit . Before cycle ( within 7 day last dose ) - You complete physical exam . - Your performance status record . - You ask side effect may experience . - If able become pregnant , blood ( 1 teaspoon ) urine pregnancy test . To take part study , must pregnant . After end Cycles 2 , 4 6 , chest x-ray either CT scan , MRI scan , PET scan check status cancer . You chest x-ray either CT scan , MRI scan , PET scan end every 3 cycle ( Cycle 9 , 12 , 15 , ) check status cancer . Length Study : You continue take study drug combination study , long disease get bad experience intolerable side effect . End-of-Study Visit : Once stop take study drug combination , come back end-of-study visit follow tests/procedures perform : - You complete physical exam . - Your performance status record . - Blood may draw ( 1 tablespoon ) routine test - You may CT scan , MRI scan , PET check status cancer , depend study doctor think necessary . Follow-Up : The status disease followed-up long possible complete study . Once every 8 week , either contact phone ask feeling ( take 5-10 minute ) , ask come clinic routine visit . You CT MRI scan every 12 week ( another anticancer therapy start ) check status cancer . This investigational study . Each study drug FDA approve commercially available . The combination valproic acid plus one study drug investigational study . Valproic acid FDA approve treatment simple complex absence seizure , complex partial epileptic seizure , acute mania , migraine prophylaxis . Dasatinib FDA approve treatment acute lymphoid leukemia ( ALL ) chronic myeloid leukemia ( CML ) . Erlotinib hydrochloride FDA approve treatment carcinoma pancreas non-small-cell lung cancer . Lapatinib FDA approve treatment breast cancer ( inflammatory , relapse , refractory ) metastatic breast cancer ( HER2 overexpression ) . Lenalidomide FDA approve treatment multiple myeloma myelodysplastic syndrome . Sorafenib FDA approve treatment renal cell carcinoma . Sunitinib malate FDA approve treatment gastrointestinal stromal tumor renal cell carcinoma . Up 327 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>1 . Patients must advance solid tumor : either disease establish standard care therapy fail one prior therapy . ( treatment arm ) 2 . Patients must ECOG performance status &lt; = 2 ( 02 ) . Patients &lt; /=10 year modify Lansky scale &gt; /= 60 . Patients &gt; 10 18 year Karnovsky scale &gt; /= 60 . ( treatment arm ) 3 . Patients must normal organ marrow function define : Platelets &gt; 50,000/uL ; Creatinine clearance &gt; 20mL/min ( treatment arm ) ; Total bilirubin &lt; 5 mg/dL ( except Lapatinib arm ) ; ALT &lt; /= 6X ULN Lapatinib arm ; 4 . ( cont . ) Liver function criterion dose base individual drug : Valproic acid ALT &gt; /= 6X ULN T. Bili &gt; /= 3 , dose decrease 50 % ; Sorafenib If Child Pugh class A B , dose adjustment ; Child Pugh class C , decrease dose 50 % ( 400 mg po daily max ) ; Sunitinib If ALT &gt; /= 6X ULN T. Bili &gt; /= 3 , decrease dose 25 % ( 37.5 mg po daily max ) ; 5 . ( cont . ) Erlotinib If ALT &gt; 6X ULN T. Bili &gt; /= 3 , decrease dose 25 % ( 100 mg po daily max ) ; Lapatinib If ALT &gt; 3X ULN T. Bili &gt; 2X ULN , decrease dose 60 % ( 500750 mg po daily max ) ; Dasatinib No dose adjustment need ; Lenalidomide No dose adjustment need . 6 . Patients legal representative must able understand willing sign IRBapproved write informed consent document . ( treatment arm ) 7 . Women childbearing potential men must agree use adequate contraception prior study entry , duration study participation , 30 day last dose . ( treatment arm ) 1 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure ( NYHA Class III IV ) , unstable angina pectoris , symptomatic cardiac arrhythmia , active bleeding , active thrombosis , psychiatric illness/social situation would limit compliance study requirement . 2 . History allergic reaction study drug analog . 3 . Failure recover prior surgery within 4 week study entry . 4 . Any treatment specific tumor control within 3 week study drug ; within 2 week cytotoxic agent give weekly ( within 6 week nitrosoureas mitomycin C ) , within 4 halflives target agent half life pharmacodynamic effect last less 5 day ( include limit erlotinib , sorafenib , sunitinib , bortezomib , similar agent ) ; failure recover toxic effect therapy prior study entry . 5 . Study agent obtain reason since study provide free agent . 6 . Any prior history hypertensive crisis hypertensive encephalopathy . 7 . Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) symptomatic peripheral vascular disease 8 . Evidence bleed diathesis coagulopathy . 9 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study enrollment anticipation need major surgical procedure course study . 10 . Minor surgical procedure , exclude placement vascular access device , within 7 day prior study enrollment . 11 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study enrollment ; serious , nonhealing wound , ulcer , bone fracture .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>Advanced Cancer</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Erlotinib Hydrochloride</keyword>
	<keyword>Sunitinib Malate</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Valproic Acid</keyword>
	<keyword>SU011248</keyword>
</DOC>